Cel Sci Corporation (CVM)

[kurious]

Patient enrollment still shy of projections in Multikine Phase 3 trial • 9:48 AM
Douglas W. House, SA News Ed...
CEL-Sci Corp. (CVM +1.1%) reports that 16 patients were recruited in the Phase 3 clinical trial evaluating the safety and efficacy of Multikine (leukocyte interleukin injection) in treatment-naive patients with head and neck cancer.
The company previously announced that it expects to enroll 880 patients in the trial by the end of 2015. Enrollment at the end of July was 232. Adding August's total of 20 and September's tally brings the total up to 268 or 612 patients yet to be recruited. This equates to a recruitment rate of ~41 patients per month.
The company expects to add ~15 new hospitals to the study in the near term. Either way, it does not appear likely that full enrollment will happen by the end of next year.
Read comments
CVM price at time of publication: $0.90. Check CVM price now »

Was this email forwarded to you? Learn more about Seeking Alpha Alerts here »

Focus Articles on CVM
Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies by Sharon di Stefano
Cel-Sci Sees Rapid Enrollment For Phase III Head And Neck Cancer Trial by Sharon di Stefano
Cel-Sci's Multikine - Potential 21st Century Superdrug by The Frugal Norwegian
More News on CVM
Cel-Sci EPS of -$0.11 Aug 8, 4:30 PM ET (Seeking Alpha)
Press Releases on CVM
CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial (Business Wire)
CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients (Business Wire)
University of Minnesota Masonic Cancer Center Joins CEL-SCI’s Phase III Head & Neck Cancer Trial (Business Wire)
Related Articles on CVM
Three Biotech Stocks With Low Price But Great Potential by Craig Keolanui
Buying Teva's Immunotherapy Investment by James Stocklasar Thomas Jr.
4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce by MarketScanners
StockTalk on CVM: CVM StockTalk | Twitter CVM | Twitter $CVM | CVM Instablogs

Recent Market Alerts on CVM: All news | Earnings | Dividends | M&A | On the move